[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-traumatic-encephalopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-traumatic-encephalopathy":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,73,103,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":53,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100270060","neurologic-stem-cell-treatment-study-100270060",false,"NCT02795052","Neurologic Stem Cell Treatment Study","Neurologic Bone Marrow Derived Stem Cell Treatment Study","NEST","Inclusion Criteria:\n\n1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.\n2. Be at least 6 months post-onset of the disease.\n3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.\n4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.\n5. Be over the age of 18 and capable of providing informed consent.\n6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.\n\nExclusion Criteria:\n\n1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.\n2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.\n3. Patients must be capable of providing informed consent.\n4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .\n5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.\n6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1\u002F3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http:\u002F\u002Fmdstemcells.com\u002Fnest\u002F",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52],"Neurologic Disorders","Nervous System Diseases","Neurodegenerative Diseases","Neurological Disorders","Stroke","Traumatic Brain Injury","Cadasil","Chronic Traumatic Encephalopathy","Cerebral Infarction","Cerebral Ischemia","Cerebral Stroke","Cerebral Hemorrhage","Parkinson","Multi-System Degeneration","MSA - Multiple System Atrophy","Progressive Supranuclear Palsy","ALS","Amyotrophic Lateral Sclerosis","Neuropathy","Diabetic Neuropathies","Alzheimer Disease","Dementia","Frontotemporal Dementia","Lewy Body Disease","Cognitive Impairment","Lewy Body Variant of Alzheimer Disease",[54,55,31,32,56,57,45,58,36,51,48,59],"Neurologic Disease","Cerebral Vascular Accident","Multiple Sclerosis","Parkinsons Disease","Diabetic Neuropathy","Neurodegeneration","RECRUITING","2026-06-24",{"date":63,"type":64},"2026-06-26","ACTUAL",{"date":66,"type":64},"2016-06",{"date":68,"type":21},"2028-07-31",{"name":70,"class":71},"MD Stem Cells","INDUSTRY",3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":102},"100616199","pilot-study-evaluating-brainquants-ability-to-detect-alterations-in-white-matter-in-diffusion-mri-indicative-of-post-traumatic-lesions-100616199","NCT07302503","Pilot Study Evaluating brainQuant's Ability to Detect Alterations in White Matter in Diffusion MRI, Indicative of Post-traumatic Lesions","BQ TC-foot","Inclusion Criteria:\n\n* Male subject\n* Aged 32 to 60 years inclusive\n* Professional footballer nearing the end of their career or recently retired, or subject who has never regularly participated in sports that expose them to head trauma (particularly rugby, basketball, handball, American football, hockey, combat sports, etc.)\n\nExclusion Criteria:\n\n\\- Subject who expressed their opposition to participating in the study","MALE","32 Years","60 Years",{"count":84,"type":21},80,"OBSERVATIONAL","Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease described in boxing, but also in contact sports such as American football.\n\nSoccer, due to repeated headers, could also be associated, albeit to a lesser degree, with the development of this type of pathology.\n\nIndeed, it has been shown that playing soccer can be accompanied by cognitive impairments, and neurodegenerative brain abnormalities have been described in neuropathology studies of former professional soccer players. Subradiological brain abnormalities have been found in multimodal MRI in various sports. Similarly, a decrease in cognitive performance has been described.\n\nThe discovery of this type of anomaly in a population of professional footballers nearing the end of their careers could lead to:\n\n* The implementation of appropriate monitoring for professional footballers through early detection of lesions via MRI and cognitive disorders\n* The implementation of preventative measures for professional footballers, but also for amateur footballers from a very young age.",[34],[34,89,90,91],"Post-traumatic lesions","Neurodegenerative brain abnormalities","Professional soccer players","2025-12-10",{"date":94,"type":64},"2025-12-24",{"date":96,"type":64},"2024-09-10",{"date":98,"type":21},"2028-03",{"name":100,"class":101},"University Hospital, Strasbourg, France","OTHER",1,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":17,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":102},"100535641","phase-3-visualizing-brain-proteinopathies-using-f-18flornaptitril-pet-in-the-prediction-of-clinical-progression-of-mild-cognitive-impairment-with-either-suspected-chronic-traumatic-encephalopathy-or-alzheimers-disease-100535641","NCT06254469","Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease","Inclusion Criteria:\n\nParticipants with MCI enrolling in the trial must meet all the following criteria:\n\n1\\. Diagnosis of MCI due to suspected CTE, and with age \\>45 years, or AD, and with age \\>50 years at the time of the Screening Visit (see Inclusion Criteria 9) 2. Participants must have a trial partner who has frequent interaction with them (approximately \\>3-4 times per week), will be present for all clinic visits, and can assist in compliance with trial procedures 3. Participants, or in the Investigator's opinion, participant's legally acceptable representative, and a trial partner provide informed consent as required by IRB 4. Female participants must be either surgically sterilized or post-menopausal, defined as at least 1 year without menses as reported by the participant or have a negative serum pregnancy test 5. Willing to comply with trial procedures 6. Willing to communicate with trial personnel 7. Willing to undergo longitudinal follow-up visits at 1 and 2 years after the Imaging Visit (only for Part B) 8. CDR global score of 0.5 9. Participants with MCI due to suspected CTE must meet the diagnostic standards of possible traumatic encephalopathy syndrome as all the following criteria:\n\na. All of the following features are required: i) Persistence of symptoms for longer than 2 years; no other neurologic disorder that is more likely to account for all the clinical features; history of head trauma exposure, progressive course; and at least 1 supportive feature ii) History of head trauma exposure, typically associated with history of concussion, although may be limited to subconcussive trauma iii) Head trauma exposure is repetitive in nature iv) Demonstrated progressive course v) Delayed symptom onset vi) Self-report or observer report of cognitive dysfunction, confirmed with objective cognitive decline documented by results of formal neuropsychological testing. Cognitive decline typically affects more than 1 domain (neuropsychological tests, visuospatial, memory, and language) b. Only 1 of the following supportive features is required: i) Emotional dysregulation: including depression, anxiety, agitation, aggression, paranoid ideation, deterioration of interpersonal relationships, or suicidality ii) Behavioral change: including violence, poor impulse control, socially inappropriate behavior, avolition, apathy, change in personality, or comorbid substance abuse iii) Motor disturbance: including bradykinesia, tremor, rigidity, gait instability, dysarthria, dysphagia, or ataxia 9. Participants with MCI due to suspected AD must meet all the following criteria:\n\n1. Diagnosis of MCI due to suspected AD according to workgroups of the Diagnostic Guidelines of the National Institute on Aging and Alzheimer's Association (NIA-AA)\n2. Documented evidence of memory decline with gradual onset and slow progression for at least 1 year. If medically documented evidence is not available, an informant may provide confirmatory evidence\n3. An MMSE-2 score of 22 to 30, inclusive, at the Screening Visit\n4. Biomarker positive based on predefined plasma p-tau cutoff\n5. Modified Hachinski Ischemic Score of ˂4 at the Screening Visit\n6. Cognitive deficits do not occur exclusively in the context of delirium\n7. Cognitive deficits are not better explained by another mental disorder (e.g., major depressive disorder, schizophrenia), or other medical condition (e.g., hypothyroidism)\n8. Treated with a stable dosage regimen of acetylcholinesterase inhibitors (AchEI) and\u002For memantine for at least 4 months prior to the Screening Visit. Participants should be expected to remain on a stable dosage regimen of these medications for the duration of the trial. Participants who are not being treated with AchEI and\u002For memantine at the time of the Screening Visit due to contraindications or previous failed treatment with these medications are also eligible for inclusion, if it is expected that participants will not be treated with these medications for the duration of the trial.\n\nInclusion Criteria for Healthy Volunteers (Part A):\n\n1. Medically healthy, at the age within 3 years of any participants with MCI due to suspected CTE or AD in Part A, and with no clinically relevant findings on physical examination or laboratory results\n2. Participants must have a trial partner who has frequent interaction with them (approximately \\>3-4 times per week), will be present for all clinic visits, and can assist in compliance with trial procedures\n3. No cognitive impairment based upon cognitive assessment and as evaluated by the Investigator\n4. No first-degree family history of early-onset AD or other neurodegenerative diseases (prior to age 65)\n5. An MMSE-2 score ≥27.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding\n2. Unable to remain still for duration of imaging procedure or have an inability to tolerate neuropsychological, clinical, or PET scan studies (e.g., head tremor that may cause head motion artifact, uncontrollable psychosis, acute suicidality)\n3. History of stroke, transient ischemic attack, seizures, or other condition of the head or neck within 12 months prior to the Screening Visit that, in the Investigator's opinion, might affect circulation to the head or image interpretation\n4. Preexisting major neurologic or other physical illness that could confound results (e.g., multiple sclerosis, diabetes, cancer)\n5. Psychiatric disorder such as mania, schizophrenia, anxiety, or depression (Geriatric Depression Scale ≥10), which in the Investigator's opinion, might interfere with completing trial procedures\n6. Condition or personal circumstance that, in the Investigator's opinion, might interfere with the collection of complete, good quality data\n7. History of significant prescription drug, non-prescription drug, or alcohol abuse, including but not limited to marijuana, cocaine, heroin, or derivatives\n8. Previously received F-18 FNT at any time, or any other investigational product (IP) within the past 30 days\n9. History of allergic reactions to albumin, or severe anemia or cardiac failure in which case the use of albumin would be medically contraindicated\n10. Unstable cardiac disease or uncontrolled hypertension (systolic blood pressure \\[BP\\] \\>170 mmHg or diastolic BP \\>100 mmHg)\n11. Any use of benzodiazepines within 24 hours prior to all trial visits\n12. Plan to take ibuprofen or naproxen within 5 days before the PET scan\n13. Received any radioactive drugs or scans within the previous month or 10 half-lives of the drug, whichever is longer, or participated in imaging or other clinical research studies that might confound trial results\n14. Implants (e.g., implanted cardiac pacemakers or defibrillators, insulin pumps, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips, or other medical implants that have not been certified for MRI), a history of claustrophobia in MRI, or any contraindication for MRI\n15. History of any CT\u002FMRI finding such as mass lesions or brain infection that are unrelated to the trial\n16. Participated in another clinical trial for an investigational agent (other than monoclonal antibody) and taken at least one dose of trial drug, unless confirmed as placebo, within 90 days prior to the Screening Visit. The end of a previous investigational trial is defined as the date of the last dose of trial drug\n17. Monoclonal antibody treatment within the previous 180 days prior to the Screening Visit\n18. Plan to receive treatment of aducanumab, lecanemab, or other potentially approved treatment options for Early AD during the trial.",true,"45 Years",{"count":112,"type":21},230,[114],"PHASE3","CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of \\[F-18\\]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected Chronic Traumatic Encephalopathy (CTE) or Alzheimer's Disease (AD).\n\nThe primary objectives of the study are to: (1) To determine the accuracy of F-18 FNT-PET in prediction of clinical decline and (2) To assess the safety and tolerability of F-18 FNT.\n\nThe secondary objectives include: (1) To demonstrate the feasibility of F-18 FNT-PET in differentiation of participants with suspected chronic traumatic encephalopathy (CTE) from those with suspected Alzheimer's disease (AD) by trained image readers, (2) To evaluate disease progression in participants with suspected CTE or AD and (3) To evaluate the correlation between F-18 FNT-PET regional and summary visual reads scan and other assessments.",[47,34],"2025-07-25",{"date":119,"type":64},"2025-07-30",{"date":121,"type":64},"2025-07-01",{"date":123,"type":21},"2029-06-30",{"name":125,"class":71},"CereMark Pharma, LLC",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":109,"sex":80,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":102},"100302530","post-concussion-syndrome-in-professional-athletes-a-multidisciplinary-study-100302530","NCT03218332","Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary Study","Inclusion Criteria:\n\nfluent in English, and a history of multiple concussions , low exposures , or no concussions (Control group ). Determination of concussion exposure will be determined as follows: Previous concussion will be based on the player's recall of injury and defined as \"an injury resulting from a blow to the head that caused an alteration in mental status and one or more of the following symptoms: headache, nausea, vomiting, dizziness\u002Fbalance problems, fatigue, trouble sleeping, drowsiness, sensitivity to light or noise, blurred vision, difficulty remembering, and difficulty concentrating.\n\nExclusion Criteria:\n\nNeurological disorders prior to concussions (e.g.: seizure disorder); systemic illnesses known to affect the brain (e.g., diabetes and lupus); a history of psychotic disorder; known developmental disorders (e.g., attention deficit disorder, dyslexia); history of migraines; and, active engagement in litigation.","25 Years","85 Years",{"count":135,"type":21},150,"to examine the relationship between repeated concussions and late decline of brain function. In addition, all participants agreeing to participate in the study will be asked to will their brains to The Krembil Neuroscience Centre Concussion Project at the Toronto Western Hospital with the consent and full knowledge of their families and doctors. However, it is possible to participate in the research without agreeing to a brain donation.\n\nThe Project Team is specifically attempting a clinical-MRI-brain tissue research analysis to determine the exact mechanism of the damage to brain tissue following repeated concussions. This condition is known as chronic traumatic encephalopathy (CTE), and shows an abnormal protein in the brain called tau-protein.",[34],"2021-09-27",{"date":140,"type":64},"2021-09-29",{"date":142,"type":64},"2011-07-04",{"date":144,"type":21},"2030-12-30",{"name":146,"class":101},"University Health Network, Toronto"]